ArticleClinical and translational science2024

Translational findings support regimen selection for first-in-human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer.

Min Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.